Clinical trials: Enoxaparin, completed
Venous Thromboembolism
Prevention of Venous Thromboembolism in Patients Undergoing Elective Total Knee Replacement Surgery
The primary objective was to demonstrate the dose-response of Semuloparin sodium (AVE5026) for the prevention of Venous Thromboembolism [VTE] in patients undergoing total knee replacement [TKR] surgery.
- Trial name
- TREK (NCT00331838)
- Testing
- Semuloparin sodium, Enoxaparin sodium
- Where
- 19 sites in Argentina, Bulgaria and 17 more
- Volunteers
- 705 people
- Sponsor
- Sanofi
Venous Thromboembolism
Study to Assess the Safety and Efficacy of SelK2 to Prevent Blood Clots in Patients Undergoing Total Knee Replacement
The main purpose of this study is to determine if an investigational medication called SelK2 works in preventing a condition called "venous thromboembolism" (VTE) in patients having a total knee replacement.
- Trial name
- COURSE (NCT03812328)
- Testing
- SelK2, Enoxaparin
- Where
- 21 sites in Bulgaria, Latvia and 3 more
- Volunteers
- 207 people
- Sponsor
- Tetherex Pharmaceuticals Corporation
Thrombosis
A Study of the Safety and Pharmacokinetics of Apixaban Versus Vitamin K Antagonist (VKA) or Low Molecular Weight Heparin (LMWH) in Pediatric Subjects With Congenital or Acquired Heart Disease Requiring Anticoagulation
To investigate the safety and pharmacokinetics of apixaban in children with congenital or acquired heart disease who have a need for anticoagulation.
- Trial name
- NCT02981472
- Testing
- Apixaban, Vitamin K Antagonist (VKA), Low Molecular Weight Heparin (LMWH)
- Where
- 46 sites in United States, Argentina and 12 more
- Volunteers
- 192 people
- Sponsor
- Bristol-Myers Squibb
Venous Thromboembolism
Efficacy and Safety of TAK-442 in Subjects Undergoing Total Knee Replacement
The purpose of this study is to determine if TAK-442, once daily (QD) or twice daily (BID), is as safe and effective as enoxaparin in preventing the development of blood clots after knee replacement surgery.
- Trial name
- NCT00641732
- Testing
- TAK-442, Enoxaparin
- Where
- 64 sites in United States, Canada
- Volunteers
- 1,045 people
- Sponsor
- Takeda
Acute Cholecystitits
The Role of Antibiotic Treatment in Patients With Acute Mild Cholecystitis - A Prospective Randomized Controlled Trial
The treatment of acute cholecystitis includes limited oral intake, antibiotics and early or delayed surgery. To date there are no randomized trials proving the benefit of antibiotic treatment.
- Trial name
- NCT00557453
- Testing
- Antibiotic treatment, No antibiotics
- Where
- Israel
- Volunteers
- 120 people
- Sponsor
- Hadassah Medical Organization
Patients Undergoing Microvascular Surgery
Use of Bemiparine as a Prophylactic Antithrombotic Agent, in Patients Undergoing Microsurgery for Head and Neck Reconstruction
A comparative study to reveal if the use of Bemiparine (Hibor) versus Enoxaparin (Clexane) as an antithrombotic agent, shows an advantage on the rate of thrombotic and haemorrhagic events in microsurgicals free flaps during head…
- Trial name
- NCT02808273
- Testing
- Bemiparine
- Where
- Spain
- Volunteers
- 78 people
- Sponsor
- Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal
Venous Thrombosis
Efficacy and Safety Study of Apixaban for the Treatment of Deep Vein Thrombosis or Pulmonary Embolism
The purpose of this study is to evaluate the effects of an investigational blood thinner, apixaban, in preventing venous thromboembolic (VTE) recurrence or death in patients with deep vein thrombosis (DVT) or pulmonary embolism…
- Trial name
- NCT00643201
- Testing
- Enoxaparin, warfarin
- Where
- 381 sites in United States, Argentina and 29 more
- Volunteers
- 5,614 people
- Sponsor
- Bristol-Myers Squibb
Prevention of Venous Thromboembolism After Knee Arthroplasty
SHR-2004 for the Prevention of Venous Thromboembolism in Patients Undergoing Total Knee Arthroplasty
The purpose of the study is to evaluate the efficacy and safety of SHR-2004 in preventing venous thromboembolism after elective unilateral total knee arthroplasty
- Trial name
- NCT05752461
- Testing
- SHR-2004 injection, Enoxaparin sodium injection
- Where
- China
- Volunteers
- 353 people
- Sponsor
- Beijing Suncadia Pharmaceuticals Co., Ltd
Enoxaparin Sodium is Administered to Healthy Volunteers
Bioavailability Study of Enoxaparin Sodium Chemi and Clexane s.c.
The primary objective of the trial is to assess the single-dose relative bioavailability of Chemi Enoxaparin (80 mg/0.8 mL) and Clexane® (80 mg/0.8 mL) administered by subcutaneous (s.c.) injection, under fasting conditions in…
- Trial name
- NCT02232802
- Testing
- Enoxaparin Sodium
- Where
- United Kingdom
- Volunteers
- 47 people, healthy volunteers welcome
- Sponsor
- Chemi S.p.A.
Venous Thromboembolism
Dose-ranging Study of Once-daily Regimen of BAY 59-7939 in the Prevention of VTE in Patients Undergoing Elective Total Hip Replacement
The purpose of this study is to assess different doses of a new drug (BAY 59-7939), taken as a tablet, are safe and can help prevent blood clots forming after a hip replacement operation.
- Trial name
- ODIXaHIP-OD (NCT00396786)
- Testing
- Rivaroxaban (Xarelto, BAY59-7939), Enoxaparin
- Where
- 62 sites in Austria, Belgium and 11 more
- Volunteers
- 877 people
- Sponsor
- Bayer
Venous Thrombosis
Evaluation of PD 0348292 for Preventing Blood Clots in the Lungs or Deep Leg Veins of Patients After Knee Surgery
To study the safety and effectiveness of several doses of PD 0348292 compared to enoxaparin in preventing blood clots in the lungs or deep leg veins of patients after knee surgery
- Trial name
- NCT00306254
- Testing
- PD 0348292, Enoxaparin
- Where
- 134 sites in United States, Australia and 14 more
- Volunteers
- 1,225 people
- Sponsor
- Pfizer
COVID-19 Pandemic
Safety and Efficacy of Enoxaparin and Hydroxychloroquine in COVID-19
In this randomized controlled study, two hundred patients with positive PCR and laboratory confirmed COVID-19 will be classified randomly into four groups.
- Trial name
- NCT05311813
- Testing
- Enoxaparin, Hydroxychloroquine
- Where
- Egypt
- Volunteers
- 200 people
- Sponsor
- Beni-Suef University
Venous Thromboembolism, Traumatic Brain Injury
Delayed Versus Early Enoxaparin Prophylaxis After Traumatic Brain Injury (TBI)
Brain injured patients are at high risk for forming blood clots in the legs and lungs. For non-brain injured trauma patients, we decrease the chances of these blood clots forming by placing the patients on a low dose of the blood…
- Trial name
- DEEP (NCT01014403)
- Testing
- enoxaparin
- Where
- 2 sites in United States
- Volunteers
- 62 people
- Sponsor
- University of Texas Southwestern Medical Center
Venous Thromboembolism (VTE)
Acute Medically Ill VTE Prevention With Extended Duration Betrixaban Study (The APEX Study)
The purpose of this study is to evaluate whether extended prophylaxis with oral betrixaban can prevent blood clots in the leg and lung that sometime occur in patients hospitalized for an acute medical illness and to compare these…
- Trial name
- APEX (NCT01583218)
- Testing
- Betrixaban, Enoxaparin
- Where
- 462 sites in United States, Argentina and 32 more
- Volunteers
- 7,513 people
- Sponsor
- Portola Pharmaceuticals
Meningioma
A Comparative Study of Prophylactic Anticoagulation in Meningioma Surgery
The aim of the study is to compare different strategies for prevention of venous thromboembolism related to intracranial meningioma surgery.
- Trial name
- NCT01941602
- Testing
- prophylactic enoxaparin, non-prophylactic
- Where
- 3 sites in Norway, Sweden
- Volunteers
- 979 people
- Sponsor
- St. Olavs Hospital
ST-elevation Myocardial Infarction
The Short- and Long Term Outcomes of Early Routine PCI With the Standard Treatment in Low-intermediate Risk ST-elevation Myocardial Infarction Patients Who Successfully Fibrinolysis.
1. Objective: To evaluate short- and long-term in the STEMI patients who successfully thrombolysis with early routine and delay percutaneous coronary intervention in low-intermediate risk patients. 2.
- Trial name
- NCT02131103
- Testing
- Percutaneous coronary intervention
- Where
- Thailand
- Volunteers
- 130 people
- Sponsor
- Chiang Mai University
Atrial Fibrillation, Stroke
Anticoagulation With Rivaroxaban in Cardioversion -The ARC Study
The purpose of this study is to determine that a new drug called "Rivaroxaban®" is effective in preventing patients from forming clots after their heart rhythm has been reset by the cardiologist with an electrical device.
- Conditions
- Atrial Fibrillation, Stroke, Thrombo-embolism, Bleeding
- Trial name
- ARC (NCT01747746)
- Testing
- Rivaroxaban, Warfarin and Enoxaparin
- Where
- United States
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- Cook County Health
Healthy Participants
A Study to Investigate Andexanet Dosing and the Interaction Between Andexanet and Subsequent Enoxaparin in Healthy Participants
The purpose of this study is to characterize andexanet posology and interaction between andexanet and enoxaparin post infusion in healthy participants.
- Trial name
- NCT07312851
- Testing
- Andexanet alfa, Rivaroxaban, Apixaban
- Where
- 2 sites in Germany, United Kingdom
- Volunteers
- 191 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Acute Coronary Syndrome
Enoxaparin Versus Unfractionated Heparin in Subjects Who Present to the Emergency Department With Acute Coronary Syndrome (RESCUE)
The purpose of this study is to determine the efficacy and safety of enoxaparin compared to unfractionated heparin (UFH) for patients diagnosed with Acute Coronary Syndrome (ACS) in the emergency department (ED).
- Trial name
- NCT00077818
- Testing
- Enoxaparin sodium
- Sponsor
- Sanofi
Knee Arthroplasty, Total
FactOr XIa inhibiTion for the pRevention of venOus Thromboembolism in Patients Undergoing Total Knee Arthroplasty
This study was to compare the study drug BAY1213790 to existing therapies, i.e. enoxaparin or apixaban, for the prevention of blood clotting and safety in patients undergoing total knee arthroplasty (TKA).
- Trial name
- FOXTROT (NCT03276143)
- Testing
- Enoxaparin, Apixaban, BAY1213790
- Where
- 54 sites in Bulgaria, Canada and 11 more
- Volunteers
- 813 people
- Sponsor
- Bayer